Ayelet Chajut
Profile
Ayelet Chajut worked as Vice President-Research at Pluri, Inc., Vice President-Research at Quark Pharmaceuticals, Inc., and Executive Vice President-Research & Development at Rosetta Genomics Ltd.
She holds a doctorate degree from Tel-Aviv University.
Former positions of Ayelet Chajut
| Companies | Position | End |
|---|---|---|
Quark Pharmaceuticals, Inc.
 Quark Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Quark Pharmaceuticals, Inc. discovers and develops novel RNAi-based therapeutics. The firm’s products include QPI-1002 and QPI-1007 is being developed as a neuroprotective agent for the treatment of optic neuropathies that result in the death of retinal ganglion cells. The company was founded by Daniel Zurr, David M. Fineman and J. Gregory Swendsen in December 1993 and is headquartered in Fremont, CA. | Chief Tech/Sci/R&D Officer | - |
| PLURI INC. | Chief Tech/Sci/R&D Officer | - |
| ROSETTA GENOMICS LTD. | Chief Tech/Sci/R&D Officer | - |
Training of Ayelet Chajut
| Tel-Aviv University | Doctorate Degree |
Experiences
Positions held
Linked companies
| Listed companies | 2 |
|---|---|
| ROSETTA GENOMICS LTD. | Health Technology |
| PLURI INC. | Health Technology |
| Private companies | 1 |
|---|---|
Quark Pharmaceuticals, Inc.
Quark Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Quark Pharmaceuticals, Inc. discovers and develops novel RNAi-based therapeutics. The firm’s products include QPI-1002 and QPI-1007 is being developed as a neuroprotective agent for the treatment of optic neuropathies that result in the death of retinal ganglion cells. The company was founded by Daniel Zurr, David M. Fineman and J. Gregory Swendsen in December 1993 and is headquartered in Fremont, CA. | Health Technology |
- Stock Market
- Insiders
- Ayelet Chajut
